13 results about "Clinical marker" patented technology

An MRI image processing and analysis system may identify instances of structure in MRI flow data, e.g., coherency, derive contours and / or clinical markers based on the identified structures. The system may be remotely located from one or more MRI acquisition systems, and perform: error detection and / or correction on MRI data sets; segmentation; visualization of flow superimposed on anatomical structure, quantification; verification; and / or generation of patient specific 4-D flow protocols. A protected health information (PHI) service is provided which de-identifies medical study data and allows medical providers to control PHI data, and uploads the de-identified data to an analytics service provider (ASP) system. A web application is provided which merges the PHI data with the de-identified data while keeping control of the PHI data with the medical provider. A Trusted Broker Service (TBS) is integrated with the PHI service pipeline and allows an authorized third party to control access to data that has been uploaded to the ASP from an authorized uploader.

The application provides a clinical marker screening method and system after metabolic response typing and application. Specifically, according to the change of metabolic indexes of normal weight people and overweight / obese people before and after meals, three clusters based on respiratory quotient (RQ) are found; the fasting fat oxidation capacity, postprandial metabolic response and postprandial blood glucose response of people belonging to different clusters also have different dynamic change patterns. In addition, key biomarkers distinguishing the three clusters are also found; the prediction model constructed by using the key biomarkers can accurately divide the subjects into three RQ clusters and can be used for predicting the results of weight loss intervention and life intervention guidance. The system constructed according to the clinical markers of the application has high sensitivity and accuracy, the indexes used are easy to obtain, and has good clinical application prospect.

The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with colorectal cancer (CRC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of CRC to metastatic CRC (mCRC) in a subject, as well as compositions for the detection thereof. The present invention also extends to clinical markers and compositions for use in the treatment and / or prognosis of CRC and in particular mCRC.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

Provided are methods of determining risk for chronic stress and stroke. More specifically, provided is an early prognostic index that can be used to predict chronic stress and stroke risk. There is provided a method of evaluating the risk of developing chronic stress and stroke, the method including obtaining a biological sample from an individual; measuring the levels of a set of biomarkers in the biological sample obtained from the individual; measuring the levels of a set of clinical markers of the individual; using a computer to programmatically generate an index based on the levels of biomarker in the biological sample obtained from the individual in combination with levels of the individual's clinical marker; and using the index to identify a likelihood that the individual will experience chronic stress and stroke.

A personalized method for providing at least one dental aligner; the method being with reference to an actual state of the dentition of the patient and in view of an improvement plan of the alignment targeted over a period of time ranging from 1 to 16 weeks, of the teeth of a subject. The method includes the steps of: (i) providing a 2D image and / or 3D volume of the dentition of a subject showing a non-alignment of its dentition; (ii) recovering clinical markers of the subject; (iii) producing an initial set of manufacturing parameters of the at least one aligner; (iv) building up an image of the 1-16 weeks target of improvement; and (v) directly 3D printing of the at least one personalized aligner fitting with the predicted evolution of intermediate tooth displacement for each tooth of the patient during the improvement plan.

The invention discloses an aging assessment method for healthy women. According to the method, a healthy female biological age calculation model is constructed by using clinical common markers, so that the evaluation of the body aging condition of the female in a non-illness state is realized, and when personalized health guidance and intervention measures are made for the sub-health transition female, an aging quantitative index can be provided, and earlier and more effective health management can be assisted to be realized. Meanwhile, compared with DNA methylation and omics related detection, the method is low in cost, high in cost performance and more beneficial to clinical popularization, and helps to achieve earlier and more effective health management.

The invention discloses an aging assessment system for healthy males, which is characterized by comprising a data acquisition module, a data preprocessing module, a biological age calculation module and an aging assessment module. According to the method, the biological age calculation model of the healthy male is constructed by using the clinical common markers, so that the evaluation of the body aging condition of the male in a non-illness state is realized, and when personalized health guidance and intervention measures are formulated for the male in sub-health transition, the aging quantitative indexes can be provided, and earlier and more effective health management can be assisted to be realized. Meanwhile, compared with DNA methylation and omics related detection, the method is low in cost, high in cost performance and more beneficial to clinical popularization, and helps to achieve earlier and more effective health management.

This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.

Described are methods related to the use of vitamin E as a clinical marker in subjects suffering from severe hypertriglyceridemia. One particular method comprises measuring a level of vitamin E in a subject's blood suffering from severe hypertriglyceridemia to assess a blood level of chylomicrons-related triglycerides. Another particular method comprises measuring a level of vitamin E in a subject's blood suffering from severe hypertriglyceridemia to distinguish between triglycerides and lipoproteins issued from the exogenous pathway versus those of the endogenous pathway. Another particular method comprises measuring vitamin E in a subject suffering from severe hypertriglyceridemia for assessing whether hypolipidemic treatments are effective or not, and to which extent. Another particular method is for assessing a risk of acute pancreatitis in a subject suffering from hypertriglyceridemia. Also described is a method for assessing vitamin E deficiency and kits comprising vitamin E.

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating CVD complications. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of CVD complications.

A personalized method for providing at least one dental aligner; the method being with reference to an actual state of the dentition of the patient and in view of an improvement plan of the alignment targeted over a period of time ranging from 1 to 16 weeks, of the teeth of a subject. The method includes the steps of: (i) providing a 2D image and / or 3D volume of the dentition of a subject showing a non-alignment of its dentition; (ii) recovering clinical markers of the subject; (iii) producing an initial set of manufacturing parameters of the at least one aligner; (iv) building up an image of the 1-16 weeks target of improvement; and (v) directly 3D printing of the at least one personalized aligner fitting with the predicted evolution of intermediate tooth displacement for each tooth of the patient during the improvement plan.

The present application relates to the biomedical field, and particularly to a clinical marker for monitoring CRS progress after CAR-T treatment and application thereof, the cytokine release syndrome (CRS) progress is judged by the expression of apolipoprotein A-1, so that effective treatment can be carried out and new treatment methods can be developed. The present application discloses APOA1 for the first time to monitor the cytokine release syndrome (CRS) progress after CAT-T treatment, and it is found through mass spectrometry and biochemical detection that APOA1 is expressed the lowest when the inflammation of the cytokine release syndrome (CRS) patient is the most serious, and with the recovery of the inflammation, its expression is also gradually recovered to the pre-treatment, and the cytokine release syndrome (CRS) progress of the patient has good consistency. These results suggest that APOA1 is an important clinical indicator for monitoring the cytokine release syndrome (CRS).